Association of Nonalcoholic Fatty Liver Disease with Bone Mineral Density and Serum Osteocalcin Levels in Korean Men

Overview

Journal Eur J Gastroenterol Hepatol

Specialty Gastroenterology

Date 2015 Dec 5

PMID 26636404

Citations 22

Authors

Hae Jin Yang

Sang Goon Shim

Bong Oh Ma

Ji Yeong Kwak

Affiliations

Soon will be listed here.

Abstract

Objective: Bone mineral density has been reported to negatively associate with nonalcoholic fatty liver disease. Osteocalcin, a bone formation marker and metabolic regulator, has been previously evaluated as the mediator between bone mineral density and nonalcoholic fatty liver disease. Herein, we aimed to investigate the correlations of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men.

Methods: A total of 859 men (249 and 610 men with and without nonalcoholic fatty liver disease, respectively) were recruited for this retrospective cross-sectional study. All participants underwent hepatic ultrasonography and dual energy X-ray absorptiometry. Anthropometric and biochemical data, including the serum osteocalcin levels and homeostasis model assessment of insulin resistance (HOMA-IR), were collected.

Results: Nonalcoholic fatty liver disease negatively associated with right-hip bone mineral density (odds ratio, 0.797; 95% confidence interval, 0.645-0.984; P=0.035) and serum osteocalcin (odds ratio, 0.948; 95% confidence interval, 0.910-0.988; P=0.011) after adjusting for BMI and HOMA-IR. The mean right-hip bone mineral density was lower in men with versus without nonalcoholic fatty liver disease after adjusting for serum osteocalcin, BMI and HOMA-IR (0.11±0.06 vs. 0.29±0.04; P=0.019).

Conclusion: Nonalcoholic fatty liver disease negatively associated with right-hip bone mineral density and serum osteocalcin in Korean men. General population-based prospective studies evaluating the causal relationship between bone metabolism and nonalcoholic fatty liver disease are needed, and the mechanism linking nonalcoholic fatty liver disease to bone mineral density beyond insulin resistance and osteocalcin should be evaluated in the future.

Citing Articles

Nonlinear association between liver fat content and lumbar bone mineral density in overweight and obese individuals: evidence from a large-scale health screening data in China.

Liu A, Sun Y, Qi X, Zhou Y, Zhou J, Li Z Endocrine. 2025; .

PMID: 39869295 DOI: 10.1007/s12020-025-04168-0.

Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study.

Chen H, Chen S, Liu D, Liang Y, Li H, Bao Y Cell Rep Med. 2025; 6(1):101884.

PMID: 39765230 PMC: 11866451. DOI: 10.1016/j.xcrm.2024.101884.

Bone Turnover Markers in Adults with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Li C, Cui Y, Zhou W, Zhang Y, Huang X, Yu F Int J Endocrinol. 2024; 2023:9957194.

PMID: 39263527 PMC: 11390221. DOI: 10.1155/2023/9957194.

Osteokines in Nonalcoholic Fatty Liver Disease.

Vachliotis I, Anastasilakis A, Rafailidis V, Polyzos S Curr Obes Rep. 2024; 13(4):703-723.

PMID: 39225951 DOI: 10.1007/s13679-024-00586-9.

osteoclast differentiation enhanced by hepatocyte supernatants from high-fat diet mice.

Wang Y, Zhou F, Shu S, Wu Y, Tian H, Li Y Biochem Biophys Rep. 2024; 39:101788.

PMID: 39108622 PMC: 11301062. DOI: 10.1016/j.bbrep.2024.101788.

References

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

Ishii S, Cauley J, Crandall C, Srikanthan P, Greendale G, Huang M . Diabetes and femoral neck strength: findings from the Hip Strength Across the Menopausal Transition Study. J Clin Endocrinol Metab. 2011; 97(1):190-7. PMC: 3251942. DOI: 10.1210/jc.2011-1883. View

Cui R, Sheng H, Rui X, Cheng X, Sheng C, Wang J . Low bone mineral density in chinese adults with nonalcoholic Fatty liver disease. Int J Endocrinol. 2013; 2013:396545. PMC: 3747470. DOI: 10.1155/2013/396545. View

Ferron M, McKee M, Levine R, Ducy P, Karsenty G . Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2011; 50(2):568-75. PMC: 3181267. DOI: 10.1016/j.bone.2011.04.017. View

Yilmaz Y, Kurt R, Eren F, Imeryuz N . Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand J Clin Lab Invest. 2011; 71(8):631-6. DOI: 10.3109/00365513.2011.604427. View

. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2014; 19(4):325-48. PMC: 3894432. DOI: 10.3350/cmh.2013.19.4.325. View

Greco E, Francomano D, Fornari R, Marocco C, Lubrano C, Papa V . Negative association between trunk fat, insulin resistance and skeleton in obese women. World J Diabetes. 2013; 4(2):31-9. PMC: 3627415. DOI: 10.4239/wjd.v4.i2.31. View

Collier J . Bone disorders in chronic liver disease. Hepatology. 2007; 46(4):1271-8. DOI: 10.1002/hep.21852. View

Arikan S, Tuzcu A, Bahceci M, Ozmen S, Gokalp D . Insulin resistance in type 2 diabetes mellitus may be related to bone mineral density. J Clin Densitom. 2012; 15(2):186-90. DOI: 10.1016/j.jocd.2011.11.005. View

10.

Aller R, Perez Castrillon J, de Luis D, Conde R, Izaola O, Gonzalez Sagrado M . Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease. Ann Hepatol. 2011; 10(1):50-5. View

11.

von Muhlen D, Safii S, Jassal S, Svartberg J, Barrett-Connor E . Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int. 2007; 18(10):1337-44. DOI: 10.1007/s00198-007-0385-1. View

12.

Faulhaber G, Premaor M, Moser Filho H, Silla L, Furlanetto T . Low bone mineral density is associated with insulin resistance in bone marrow transplant subjects. Bone Marrow Transplant. 2009; 43(12):953-7. DOI: 10.1038/bmt.2009.70. View

13.

Solaymani-Dodaran M, Card T, Aithal G, West J . Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology. 2006; 131(6):1752-7. DOI: 10.1053/j.gastro.2006.09.012. View

14.

Yilmaz Y . Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk. Aliment Pharmacol Ther. 2012; 36(4):345-52. DOI: 10.1111/j.1365-2036.2012.05196.x. View

15.

Pardee P, Dunn W, Schwimmer J . Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther. 2011; 35(2):248-54. PMC: 4624396. DOI: 10.1111/j.1365-2036.2011.04924.x. View

16.

Gupte A, Sabek O, Fraga D, Minze L, Nishimoto S, Liu J . Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome. Endocrinology. 2014; 155(12):4697-705. PMC: 5393336. DOI: 10.1210/en.2014-1430. View

17.

Pittas A, Harris S, Eliades M, Stark P, Dawson-Hughes B . Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2008; 94(3):827-32. PMC: 2681283. DOI: 10.1210/jc.2008-1422. View

18.

Ferron M, Hinoi E, Karsenty G, Ducy P . Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008; 105(13):5266-70. PMC: 2278202. DOI: 10.1073/pnas.0711119105. View

19.

Jin L, Chang S, Koh S, Kim K, Lee T, Ryu S . Association between alcohol consumption and bone strength in Korean adults: the Korean Genomic Rural Cohort Study. Metabolism. 2010; 60(3):351-8. DOI: 10.1016/j.metabol.2010.02.012. View

20.

Menon K, Angulo P, Weston S, Dickson E, Lindor K . Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001; 35(3):316-23. DOI: 10.1016/s0168-8278(01)00144-1. View